Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP
Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP

Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP

Endocrinol Diabetes Nutr (Engl Ed). 2025 Oct 18:501639. doi: 10.1016/j.endien.2025.501639. Online ahead of print.

ABSTRACT

Type 1 diabetes (T1D) is an autoimmune disease whose late diagnosis can lead to serious complications such as diabetic ketoacidosis, especially in children. The presence of specific autoantibodies allows for the identification of a presymptomatic phase, opening the door to screening strategies targeting populations at high genetic risk, such as first-degree relatives. This document presents the consensus recommendations of the Spanish Diabetes Society (SED), the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Society of Paediatric Endocrinology (SEEP) on the screening, staging and monitoring of T1D in preclinical stages. Early identification of the disease will enable a personalised approach to be established, promote health education and, eventually, consider therapeutic interventions that may delay progression to the symptomatic phase. This consensus seeks to establish a common framework for clinical action based on the available evidence, with clear recommendations for its proper implementation.

PMID:41111054 | DOI:10.1016/j.endien.2025.501639